Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588228 | 1.00 | CYP1A2 (0.57) | CYP1A2POLBCASP3GAAATM | |
| SCHEMBL14960133 | 0.84 | POLB (0.61) | CYP1A2POLBGAAMPOKDM4E | |
| SCHEMBL28910016 | 0.82 | CASP3 (0.45) | CYP1A2CASP3GAAATMMPO | |
| SCHEMBL2534941 | 0.81 | KDM4E (0.62) | CASP3MPOKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3906125 | 0.81 | GAA (0.47) | CYP1A2CASP3GAAATMMPO | |
| SCHEMBL4250865 | 0.81 | LMNA (0.68) | POLBCASP3GAAATMMPO | |
| SCHEMBL6490329 | 0.81 | CASP3 (0.47) | CYP1A2CASP3GAAATMMPO | |
| SCHEMBL439684 | 0.81 | NCF1 (0.59) | CASP3MPOALDH1A1HSD17B10BCHE | |
| SCHEMBL20277833 | 0.81 | CASP3 (0.44) | CYP1A2CASP3GAAATMMPO | |
| SCHEMBL3531515 | 0.79 | LMNA (0.66) | CYP1A2POLBGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380741-B | Preparation method of 4-position alkylated derivative of 2-methylquinoline compound | 济南大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-114380741-A | Preparation method of 4-position alkylated derivative of 2-methylquinoline compound | 济南大学 | 2022-04-22 | — | — | CN | disclosed |
| WO-2021191359-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200131148-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160185726-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185726-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | CYP1A2 69/4885POLB 4289/4885CASP3 329/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | CYP1A2 69/4885POLB 4289/4885CASP3 329/4885 |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885POLB 2502/4885CASP3 2198/4885 |
| US-20200131148-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | CYP1A2 298/4885POLB 501/4885CASP3 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.